

ADULT AMBULATORY INFUSION ORDER Ferric Derisomaltose (MONOFERRIC) Infusion

Page 1 of 3

ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Patient Identification

Weight: _____kg Height: ____cm Allergies: Diagnosis Code: _____ Treatment Start Date: Patient to follow up with provider on date: **This plan will expire after 365 days at which time a new order will need to be placed** **GUIDELINES FOR ORDERING** 1. Send FACE SHEET and H&P or most recent chart note. 2. If patient is pregnant, estimated due date is: _____

3. Provider must order and obtain ferritin prior to patient being scheduled for iron infusion. Labs drawn date:

Copy of ferritin result must be attached.

4. Many insurance providers require a ferritin result within 90 days. If ferritin is not within 90 days of signed date then patient's insurance may deny coverage for this treatment.

NURSING ORDERS:

- 1. TREATMENT PARAMETERS Hold treatment and notify provider if Ferritin greater than 300 ng/mL.
- 2. Instruct patient to set follow up appointment with provider for follow up labs.
- 3. Monitor patient for signs and symptoms of hypersensitivity during the infusion and for at least 30 minutes after completion of the infusion.
- 4. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

MEDICATIONS:

Ferric Derisomaltose (MONOFERRIC) dosing: (must check one)

- O For weight greater than or equal to 50 kg: 1,000 mg in sodium chloride 0.9% 100 mL, intravenous, ONCE, over 20 minutes
- O For weight less than 50 kg: 20 mg/kg in sodium chloride 0.9% 100 mL, intravenous, ONCE, over 20 minutes

AS NEEDED MEDICATIONS:

1. sodium chloride 0.9% bolus, intravenous, 500 mL, AS NEEDED x1 dose, for vein discomfort. Give concurrently with ferric gluconate

HYPERSENSITIVITY MEDICATIONS:

 NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER Ferric Derisomaltose (MONOFERRIC) Infusion

Page 2 of 3

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

- 2. NURSING COMMUNICATION Avoid intravenous or oral diphenhydrAMINE, move to next option in the algorithm. Adverse effects of diphenhydrAMINE may overlap with IV iron adverse effects such as flushing, hypotension, tachycardia.
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

By signing below, I represent the follow	ving:	
I am responsible for the care of the patient	t (who is identified at the top of this form);	
I hold an active, unrestricted license to pra	actice medicine in: Oregon (check box
	ovide care to patient and where you are currently license	
My physician license Number is #	(MUST BE COMPLETED TO BE A V	ALID
PRESCRIPTION); and I am acting within I	my scope of practice and authorized by law to order Infu	sion of the
PRESCRIPTION) ; and I am acting within medication described above for the patien		sion of the
		sion of the
		sion of the
		sion of the



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER

Ferric Derisomaltose (MONOFERRIC) Infusion Page 3 of 3 ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

_				
(,)	ntra	ıl Ir	1ta	ر م٠
\sim	ııuc	U 11	па	NG.

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

□ Beaverton

OHSU Knight Cancer Institute 15700 SW Greystone Court Beaverton, OR 97006

Phone number: 971-262-9000 Fax number: 503-346-8058

☐ Gresham

Legacy Mount Hood campus Medical Office Building 3, Suite 140 24988 SE Stark Gresham, OR 97030

Phone number: 971-262-9500 Fax number: 503-346-8058

□ NW Portland

Legacy Good Samaritan campus Medical Office Building 3, Suite 150 1130 NW 22nd Ave. Portland, OR 97210

Phone number: 971-262-9600 Fax number: 503-346-8058

□ Tualatin

Legacy Meridian Park campus Medical Office Building 2, Suite 140 19260 SW 65th Ave. Tualatin, OR 97062

Phone number: 971-262-9700 Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders